Not to be redundant, please keep in mind the uniqueness of our company's research. We are partners with Sheba Hospital and the costs have been incredibly minimal when compared to U.S. pharma companies research costs. This however, comes with a "cost" that most of us need to remember - Sheba acts within a timeframe, but is apparently not bound to this timeframe (aka timeline). It bothers us all, but the rewards for those long, will be a thorough and complete researched product(s) with IP in place, as well as multiple manufacturing/JV connections. An additional positive, in time, will be the academic acceptance of OWCP internationally as "The Authority" on MMJ research.
Market Data 
Markets 
AI
